Published in Thorac Cancer on June 13, 2016
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol (2013) 2.11
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer (2008) 1.71
Soft tissue metastases in lung cancer: a review of the literature. Eur Rev Med Pharmacol Sci (2012) 1.45
Skeletal muscle metastases: primary tumours, prevalence, and radiological features. Eur Radiol (2009) 1.38
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest (2005) 1.35
Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B (2015) 1.20
Modulation of EGFR gene transcription by a polymorphic repetitive sequence--a link between genetics and epigenetics. Int J Biol Markers (2000) 0.95
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol (2003) 0.83
Phenotypic and functional properties of dedifferentiated fat cells derived from infrapatellar fat pad. Regen Ther (2022) 0.75
Interleukin-17A expression in human synovial mast cells in rheumatoid arthritis and osteoarthritis. Allergol Int (2016) 0.75
The importance of Blumensaat's line morphology for accurate femoral ACL footprint evaluation using the quadrant method. Knee Surg Sports Traumatol Arthrosc (2017) 0.75